APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Vancomycin-Resistant Enterococcus Faecium

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Analysis and Forecast 2026-2032

19 December 2025190 pages

Choose your research edition.

Industry ResearchDrugs for Vancomycin-Resistant Enterococcus Faecium Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Drugs for Vancomycin-Resistant Enterococcus Faecium Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Vancomycin-Resistant Enterococcus Faecium Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Vancomycin-Resistant Enterococcus Faecium Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Drugs for Vancomycin-Resistant Enterococcus Faecium market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Drugs for Vancomycin-Resistant Enterococcus Faecium is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drugs for Vancomycin-Resistant Enterococcus Faecium is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drugs for Vancomycin-Resistant Enterococcus Faecium is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drugs for Vancomycin-Resistant Enterococcus Faecium is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Drugs for Vancomycin-Resistant Enterococcus Faecium include Microbiotix, MGB Biopharma Limited, Lytix Biopharma, LegoChem Biosciences, Helix BioMedix, Enanta Pharmaceuticals, Cellceutix Corporation, Aphios Corporation and Alvogen, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Drugs for Vancomycin-Resistant Enterococcus Faecium, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drugs for Vancomycin-Resistant Enterococcus Faecium, also provides the revenue of main regions and countries. Of the upcoming market potential for Drugs for Vancomycin-Resistant Enterococcus Faecium, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs for Vancomycin-Resistant Enterococcus Faecium revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drugs for Vancomycin-Resistant Enterococcus Faecium market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drugs for Vancomycin-Resistant Enterococcus Faecium revenue, projected growth trends, production technology, application and end-user industry.

Drugs for Vancomycin-Resistant Enterococcus Faecium Segment by Company

Microbiotix

MGB Biopharma Limited

Lytix Biopharma

LegoChem Biosciences

Helix BioMedix

Enanta Pharmaceuticals

Cellceutix Corporation

Aphios Corporation

Alvogen

Alchemia Limited

Drugs for Vancomycin-Resistant Enterococcus Faecium Segment by Type

Ampicillin

Daptomycin

Quinupristin/dalfopristin

Linezolid

Chloramphenicol

Others

Drugs for Vancomycin-Resistant Enterococcus Faecium Segment by Application

Hospital

Clinic

Others

Drugs for Vancomycin-Resistant Enterococcus Faecium Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Vancomycin-Resistant Enterococcus Faecium market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Vancomycin-Resistant Enterococcus Faecium and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Vancomycin-Resistant Enterococcus Faecium.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drugs for Vancomycin-Resistant Enterococcus Faecium in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drugs for Vancomycin-Resistant Enterococcus Faecium company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drugs for Vancomycin-Resistant Enterococcus Faecium revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Ampicillin Major Player Table 3. Daptomycin Major Player Table 4. Quinupristin/dalfopristin Major Player Table 5. Linezolid Major Player Table 6. Chloramphenicol Major Player Table 7. Others Major Player Table 8. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Hospital Major Player Table 10. Clinic Major Player Table 11. Others Major Player Table 12. Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Trends Table 13. Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Drivers Table 14. Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Opportunities and Challenges Table 15. Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Restraints Table 16. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Share by Region (2021-2026) Table 19. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Share by Region (2027-2032) Table 21. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Market Share by Players (2021-2026) Table 23. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Key Players Headquarters & Area Served Table 25. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Players, Product Type & Application Table 26. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Drugs for Vancomycin-Resistant Enterococcus Faecium by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Market Share by Type (2021-2026) Table 33. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Market Share by Type (2027-2032) Table 34. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Market Share by Application (2021-2026) Table 38. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Market Share by Application (2027-2032) Table 39. Microbiotix Company Information Table 40. Microbiotix Business Overview Table 41. Microbiotix Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Microbiotix Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 43. Microbiotix Recent Development Table 44. MGB Biopharma Limited Company Information Table 45. MGB Biopharma Limited Business Overview Table 46. MGB Biopharma Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. MGB Biopharma Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 48. MGB Biopharma Limited Recent Development Table 49. Lytix Biopharma Company Information Table 50. Lytix Biopharma Business Overview Table 51. Lytix Biopharma Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Lytix Biopharma Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 53. Lytix Biopharma Recent Development Table 54. LegoChem Biosciences Company Information Table 55. LegoChem Biosciences Business Overview Table 56. LegoChem Biosciences Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. LegoChem Biosciences Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 58. LegoChem Biosciences Recent Development Table 59. Helix BioMedix Company Information Table 60. Helix BioMedix Business Overview Table 61. Helix BioMedix Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Helix BioMedix Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 63. Helix BioMedix Recent Development Table 64. Enanta Pharmaceuticals Company Information Table 65. Enanta Pharmaceuticals Business Overview Table 66. Enanta Pharmaceuticals Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Enanta Pharmaceuticals Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 68. Enanta Pharmaceuticals Recent Development Table 69. Cellceutix Corporation Company Information Table 70. Cellceutix Corporation Business Overview Table 71. Cellceutix Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Cellceutix Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 73. Cellceutix Corporation Recent Development Table 74. Aphios Corporation Company Information Table 75. Aphios Corporation Business Overview Table 76. Aphios Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Aphios Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 78. Aphios Corporation Recent Development Table 79. Alvogen Company Information Table 80. Alvogen Business Overview Table 81. Alvogen Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Alvogen Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 83. Alvogen Recent Development Table 84. Alchemia Limited Company Information Table 85. Alchemia Limited Business Overview Table 86. Alchemia Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Alchemia Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 88. Alchemia Limited Recent Development Table 89. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2026) & (US$ Million) Table 90. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2027-2032) & (US$ Million) Table 91. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2026) & (US$ Million) Table 92. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2027-2032) & (US$ Million) Table 93. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 94. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2021-2026) & (US$ Million) Table 95. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (US$ Million) & (2027-2032) Table 96. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2026) & (US$ Million) Table 97. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2027-2032) & (US$ Million) Table 98. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2026) & (US$ Million) Table 99. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2027-2032) & (US$ Million) Table 100. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2021-2026) & (US$ Million) Table 102. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (US$ Million) & (2027-2032) Table 103. China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2026) & (US$ Million) Table 104. China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2027-2032) & (US$ Million) Table 105. China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2026) & (US$ Million) Table 106. China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2027-2032) & (US$ Million) Table 107. Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2026) & (US$ Million) Table 108. Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2027-2032) & (US$ Million) Table 109. Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2026) & (US$ Million) Table 110. Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2027-2032) & (US$ Million) Table 111. Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 112. Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Region (US$ Million) & (2021-2026) Table 113. Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Region (US$ Million) & (2027-2032) Table 114. SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2026) & (US$ Million) Table 115. SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2027-2032) & (US$ Million) Table 116. SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2026) & (US$ Million) Table 117. SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2027-2032) & (US$ Million) Table 118. SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2021-2026) & (US$ Million) Table 120. SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (US$ Million) & (2027-2032) Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. Drugs for Vancomycin-Resistant Enterococcus Faecium Image Figure 2. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size Share 2021 VS 2025 VS 2032 Figure 4. Ampicillin Image Figure 5. Daptomycin Image Figure 6. Quinupristin/dalfopristin Image Figure 7. Linezolid Image Figure 8. Chloramphenicol Image Figure 9. Others Image Figure 10. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size Share 2021 VS 2025 VS 2032 Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size (US$ Million) & (2021-2032) Figure 16. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Market Share by Type (2021-2032) Figure 23. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Market Share by Application (2021-2032) Figure 26. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Type (2021-2032) Figure 28. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Application (2021-2032) Figure 29. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Country (2021-2032) Figure 30. United States Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Type (2021-2032) Figure 35. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Application (2021-2032) Figure 36. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Country (2021-2032) Figure 37. Germany Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Type (2021-2032) Figure 47. China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Application (2021-2032) Figure 48. Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Type (2021-2032) Figure 50. Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Application (2021-2032) Figure 51. Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Region (2021-2032) Figure 52. Japan Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Type (2021-2032) Figure 60. SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Application (2021-2032) Figure 61. SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Country (2021-2032) Figure 62. Brazil Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Ampicillin
  • Daptomycin
  • Quinupristin/dalfopristin
  • Linezolid
  • Chloramphenicol
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Microbiotix
  • MGB Biopharma Limited
  • Lytix Biopharma
  • LegoChem Biosciences
  • Helix BioMedix
  • Enanta Pharmaceuticals
  • Cellceutix Corporation
  • Aphios Corporation
  • Alvogen
  • Alchemia Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drugs for Vancomycin-Resistant Enterococcus Faecium Market by Type
  3. 1.2.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Ampicillin
  5. 1.2.3 Daptomycin
  6. 1.2.4 Quinupristin/dalfopristin
  7. 1.2.5 Linezolid
  8. 1.2.6 Chloramphenicol
  9. 1.2.7 Others
  10. 1.3 Drugs for Vancomycin-Resistant Enterococcus Faecium Market by Application
  11. 1.3.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Hospital
  13. 1.3.3 Clinic
  14. 1.3.4 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Drugs for Vancomycin-Resistant Enterococcus Faecium Market Dynamics
  1. 2.1 Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Trends
  2. 2.2 Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Drivers
  3. 2.3 Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Opportunities and Challenges
  4. 2.4 Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Perspective (2021-2032)
  2. 3.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Growth Trends by Region
  3. 3.2.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size by Region (2021-2026)
  5. 3.2.3 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Players
  2. 4.1.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Players (2021-2026)
  3. 4.1.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Key Players Headquarters & Area Served
  7. 4.4 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Players, Product Type & Application
  8. 4.5 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market CR5 and HHI
  11. 4.6.3 2025 Drugs for Vancomycin-Resistant Enterococcus Faecium Tier 1, Tier 2, and Tier 3
5 Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size by Type
  1. 5.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2032)
  3. 5.3 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Market Share by Type (2021-2032)
6 Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size by Application
  1. 6.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2032)
  3. 6.3 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Microbiotix
  2. 7.1.1 Microbiotix Company Information
  3. 7.1.2 Microbiotix Business Overview
  4. 7.1.3 Microbiotix Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Microbiotix Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  6. 7.1.5 Microbiotix Recent Developments
  7. 7.2 MGB Biopharma Limited
  8. 7.2.1 MGB Biopharma Limited Company Information
  9. 7.2.2 MGB Biopharma Limited Business Overview
  10. 7.2.3 MGB Biopharma Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  11. 7.2.4 MGB Biopharma Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  12. 7.2.5 MGB Biopharma Limited Recent Developments
  13. 7.3 Lytix Biopharma
  14. 7.3.1 Lytix Biopharma Company Information
  15. 7.3.2 Lytix Biopharma Business Overview
  16. 7.3.3 Lytix Biopharma Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Lytix Biopharma Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  18. 7.3.5 Lytix Biopharma Recent Developments
  19. 7.4 LegoChem Biosciences
  20. 7.4.1 LegoChem Biosciences Company Information
  21. 7.4.2 LegoChem Biosciences Business Overview
  22. 7.4.3 LegoChem Biosciences Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  23. 7.4.4 LegoChem Biosciences Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  24. 7.4.5 LegoChem Biosciences Recent Developments
  25. 7.5 Helix BioMedix
  26. 7.5.1 Helix BioMedix Company Information
  27. 7.5.2 Helix BioMedix Business Overview
  28. 7.5.3 Helix BioMedix Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Helix BioMedix Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  30. 7.5.5 Helix BioMedix Recent Developments
  31. 7.6 Enanta Pharmaceuticals
  32. 7.6.1 Enanta Pharmaceuticals Company Information
  33. 7.6.2 Enanta Pharmaceuticals Business Overview
  34. 7.6.3 Enanta Pharmaceuticals Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Enanta Pharmaceuticals Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  36. 7.6.5 Enanta Pharmaceuticals Recent Developments
  37. 7.7 Cellceutix Corporation
  38. 7.7.1 Cellceutix Corporation Company Information
  39. 7.7.2 Cellceutix Corporation Business Overview
  40. 7.7.3 Cellceutix Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Cellceutix Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  42. 7.7.5 Cellceutix Corporation Recent Developments
  43. 7.8 Aphios Corporation
  44. 7.8.1 Aphios Corporation Company Information
  45. 7.8.2 Aphios Corporation Business Overview
  46. 7.8.3 Aphios Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Aphios Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  48. 7.8.5 Aphios Corporation Recent Developments
  49. 7.9 Alvogen
  50. 7.9.1 Alvogen Company Information
  51. 7.9.2 Alvogen Business Overview
  52. 7.9.3 Alvogen Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Alvogen Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  54. 7.9.5 Alvogen Recent Developments
  55. 7.10 Alchemia Limited
  56. 7.10.1 Alchemia Limited Company Information
  57. 7.10.2 Alchemia Limited Business Overview
  58. 7.10.3 Alchemia Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Alchemia Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  60. 7.10.5 Alchemia Limited Recent Developments
8 North America
  1. 8.1 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue (2021-2032)
  2. 8.2 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2032)
  3. 8.2.1 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2026)
  4. 8.2.2 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2027-2032)
  5. 8.3 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Type (2021-2032)
  6. 8.4 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2032)
  7. 8.4.1 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2026)
  8. 8.4.2 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2027-2032)
  9. 8.5 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Application (2021-2032)
  10. 8.6 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country
  11. 8.6.1 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2021-2026)
  13. 8.6.3 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue (2021-2032)
  2. 9.2 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2032)
  3. 9.2.1 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2026)
  4. 9.2.2 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2027-2032)
  5. 9.3 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Type (2021-2032)
  6. 9.4 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2032)
  7. 9.4.1 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2026)
  8. 9.4.2 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2027-2032)
  9. 9.5 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Application (2021-2032)
  10. 9.6 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country
  11. 9.6.1 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2021-2026)
  13. 9.6.3 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue (2021-2032)
  2. 10.2 China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2032)
  3. 10.2.1 China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2026)
  4. 10.2.2 China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2027-2032)
  5. 10.3 China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Type (2021-2032)
  6. 10.4 China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2032)
  7. 10.4.1 China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2026)
  8. 10.4.2 China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2027-2032)
  9. 10.5 China Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue (2021-2032)
  2. 11.2 Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2032)
  3. 11.2.1 Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2026)
  4. 11.2.2 Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2027-2032)
  5. 11.3 Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Type (2021-2032)
  6. 11.4 Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2032)
  7. 11.4.1 Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2026)
  8. 11.4.2 Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2027-2032)
  9. 11.5 Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Application (2021-2032)
  10. 11.6 Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country
  11. 11.6.1 Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2021-2026)
  13. 11.6.3 Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue (2021-2032)
  2. 12.2 SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Type (2027-2032)
  5. 12.3 SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Application (2027-2032)
  9. 12.5 SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country
  11. 12.6.1 SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst